280581-45-5

Basic information

• Product Name: 4-Anilino-2,5-dichloropyrimidine
• Synonyms: 4-Anilino-2,5-dichloropyrimidine
• CAS NO: 280581-45-5
• Molecular Weight: 240.092
• Mol File: 280581-45-5.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: 4-Anilino-2,5-dichloropyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Anilino-2,5-dichloropyrimidine(280581-45-5)
• EPA Substance Registry System: 4-Anilino-2,5-dichloropyrimidine(280581-45-5)

Safety Data

• Hazardous Substances Data: 280581-45-5(Hazardous Substances Data)

Upstream product

• 5750-76-5 2,4,5-trichloropyrimidine 
• 62-53-3 aniline 

Downstream Products

• 1341200-76-7 2-((2,5-dichloropyrimidin-4-yl)amino)benzene-1-sulfonyl chloride 
• 1022950-46-4 2,5-dichloro-N-(2-(pyrrolidin-1-ylsulfonyl)phenyl)pyrimidin-4-amine 
• 1341200-52-9 5-chloro-N₂-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-N₄-(2-(pyrrolidin-1-ylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1352244-87-1 5-chloro-N₂-[4-(4-methylpiperazin-1-yl)phenyl]-N₄-phenylpyrimidine-2,4-diamine trifluoroacetate (1:1) 
• 1620988-79-5 5-chloro-N²-(1-(methylsulfonyl)piperidin-4-yl)-N⁴-phenylpyrimidine-2,4-diamine 
• 280580-27-0 4-Anilino-5-chloro-2-{4-[2-hydroxy-3-(isopropylamino)propoxy]anilino}pyrimidine 
• 358789-02-3 4-anilino-2-(4-carboxyanilino)-5-chloropyrimidine 

Relevant articles and documents

Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach

B-cell lymphoma 6 (BCL6) is a transcriptional factor that expresses in lymphocytes and regulates the differentiation and proliferation of lymphocytes. Therefore, BCL6 is a therapeutic target for autoimmune diseases and cancer treatment. This report presen

Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC

Combination of anaplastic lymphoma kinase (ALK) inhibitor with histone deacetylases (HDAC) inhibitor could exert synergistically anti-proliferative effects on ALK positive non-small cell lung cancer (NSCLC) na?ve or resistant cells. In this work, we designed and synthesized a series of 2,4-pyrimidinediamine derivatives as dual ALK and HDAC inhibitors based on pharmacophore merged strategy. Among which, compound 10f displayed the most potent and balanced inhibitory activity against ALK (IC50 = 2.1 nM) and HDAC1 (IC50 = 7.9 nM), respectively. In particular, 10f was also potent against the frequently observed Crizotinib-resistant ALKL1196M (IC50 = 1.7 nM) as well as the Ceritinib-resistant ALKG1202R (IC50 = 0.4 nM) mutants. In antiproliferative activity assay, 10f exhibited impressive activity on ALK-addicted cancer cell lines at low micromole concentrations, which was comparable to that of Crizotinib and Ceritinib. Further flow cytometric analysis indicated that 10f could effectively induce cell death via cell apoptosis and cell cycle arrest. Taken together, these results suggested 10f would be a promising lead compound for the ALK-positive NSCLC treatment, especially the Ceritinib- or Crizotinib-resistant NSCLC.

5-chloro-pyrimidine-2, 4-diamine compound as well as preparation method and application thereof

The invention discloses a 5-chloro-pyrimidine-2, 4-diamine compound as well as a preparation method and an application thereof. The 5-chloro-pyrimidine-2, 4-diamine compound is shown as a formula (I)or a formula (II), wherein R1 is selected from any one g